Navigation Links
De nouvelles directives recommandent la fidaxomicine pour tous les patients pouvant suivre un traitement antibiotique par voie orale pour une infection à Clostridium difficile
Date:10/29/2013

est une étape importante pour la réduction de la morbidité et de la mortalité associée à l'ICD », déclare le professeur Oliver Cornely de l'hôpital universitaire de Cologne en Allemagne. « J'approuve ces directives et je pense que l'application de ces recommandations améliorera le traitement de l'ICD et réduira le fardeau à la fois pour les patients et les systèmes de santé. »

Deux importantes études cliniques de phase III comparant l'efficacité et l'innocuité de 400 mg par jour fidaxomicine par voie orale à 500 mg par jour de vancomycine ont permis de montrer les avantages potentiels de la fidaxomicine par rapport à la vancomycine qui est le traitement habituel.[9],[11] Les patients participant à ces essais présentaient un diagnostic confirmé d'ICD et incluaient des patients classés comme souffrant d'une ICD grave ainsi que des patients pour lesquels l'ICD constituait un risque particulièrement important comme les personnes âgées[11] ou avec des pathologies concomitantes.[12],[13],[14] La fidaxomincine a permis de réduire considérablement le taux de récurrence de l'ICD comparé à la vancomycine et les patients traités avec la fidaxomicine étaient plus susceptibles de ne plus souffrir de diarrhées sans récurrence 30 jours après la fin du traitement, que les patients traités avec de la vancomycine.[9],[11] La fidaxomicine a également atteint son critère d'évaluation principal de taux de guérison clinique qui était équivalent à celui de la vancomycine.[9],[11]

Certaines populations courent un risque plus élevé d'ICD et sont particulièrement vulnérables. L'ICD peut être as
'/>"/>

SOURCE Astellas Pharma Europe Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Medicare Procurement Program Creates Extreme Hardships For North Carolina Patients, Says AAHomecare
2. Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
3. Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis
4. 3SBio to Develop DJ5 for Progressive Renal Failure in ADPKD Patients
5. Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
6. Medicare Procurement Program Creates Extreme Hardships for Patients without Options, Says AAHomecare
7. Media Sourcerys Secure Mobile Workflow App Deployed by CCS Medical to Expedite Product Delivery to Patients
8. Lamotrigine is One of the Most Commonly Prescribed Drugs Among Newly Diagnosed Bipolar Disorder Patients in the United States
9. Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea
10. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
11. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... DALLAS and NEW YORK ... PHARMACEUTICALS, INC. (OTCBB: ACCP), has signed an exclusive, ... for the development and commercialization of its proprietary ... new corporate management team and its intention to ... Biopharmaceuticals, Inc.™, and its plans to pursue a ...
(Date:9/22/2014)... Sept. 22, 2014 Research and Markets ... Chinese Diclofenac Industry Report 2014" report to their ... Industry Report 2014 is a professional and in-depth study ... with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:9/20/2014)... 20, 2014 /CNW/ - The issue: Mylan Pharmaceuticals ULC Canada, ... of its Mylan-Nitro Spray 0.4 mg/metered dose due to the ... pump component. A missing "dip tube" could ... the patient. This defect may lead patients to believe they ... to access it. Not receiving nitroglycerin could place them at ...
Breaking Medicine Technology:Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6Global and Chinese Diclofenac Industry Report 2014 2Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2
(Date:9/22/2014)... September 22, 2014 The Spa Standard, ... to lead the start-up in developing content and courses ... to the company over 15 years of experience in ... resort spa management with companies including Orient Express Hotels ... the role of educator, Jenny gained extensive industry insight ...
(Date:9/22/2014)... the proverbial needle in the cancer antigen haystack, according ... of Experimental Medicine . , As cancer ... creates new versions of proteins, some of which are ... cells, prompting the cells to attack and eliminate the ... of the mutations in a patient,s cancer and to ...
(Date:9/22/2014)... 2014--Women who are about to be released from prison ... if they are to successfully reintegrate into their communities ... study. , Almost half of all female prisoners are ... and most have multiple prison terms, mainly for drug-related ... Michael,s Hospital, conducted one-on-one interviews with women who were ...
(Date:9/22/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... GLOBAL MARKETS, the global market for autoimmune disease ... billion by 2019, with a five-year compound annual ... holds the highest market potential due to an ... western lifestyles. , In recent decades, autoimmune ...
(Date:9/22/2014)... on Trauma, patients with severe injuries should be treated ... centers have the resources to provide the best care ... major trauma patients in 2010 actually received their treatment ... a new study from the Center for Pediatric Trauma ... at Nationwide Children,s Hospital. Those patients are "undertriaged." The ...
Breaking Medicine News(10 mins):Health News:The Spa Standard Appoints Vice-President of Content and Course Development 2Health News:Involving female offenders in release planning can increase reintegration success 2Health News:Global Market for Autoimmune Disease Diagnostics to Reach Nearly $13.1 Billion in 2019; Southern Asia Holds the Highest Potential 2Health News:Global Market for Autoimmune Disease Diagnostics to Reach Nearly $13.1 Billion in 2019; Southern Asia Holds the Highest Potential 3Health News:New study finds 34 percent of severely injured patients undertriaged in the United States 2Health News:New study finds 34 percent of severely injured patients undertriaged in the United States 3
... Health plans today proposed guaranteed coverage for people with pre-existing ... , , Under the ... market would be required to offer coverage to all applicants ... individuals were required to maintain health insurance. , ...
... Inc. (NYSE: PRX ) today announced that it ... the U.S. to market budesonide,inhalation suspension, which is a generic ... asthma. Par began,shipping 0.25 mg/2 ml and 0.5 mg/2 ... Full-year US sales for PULMICORT(R) in 2007 totalled ...
... human trial , , WEDNESDAY, Nov. 19 (HealthDay News) -- ... patients may not slow the disease, new research suggests. ... spurred by promising animal research that had suggested that ... on the brain. , However, "the study suggests that ...
... , TORONTO, Nov. 19 /PRNewswire-FirstCall/ - Bradmer ... and commercialization of cancer therapies, announced today that it ... data from Neuradiab(TM) at the Society for Neuro-Oncology,s (SNO) ... from two previously conducted Phase II trials, is titled ...
... medicine community: "Are Your Cells Free?" Learn more about InVitria at TERMIS ... ... Collins, CO (PRWEB) November 19, 2008 -- Stem cell culture researchers ... Tissue Engineering Meeting TERMIS in San Diego on Dec. 7-10. ...
... anniversary of the adoption of the United Nations Convention on the ... ARLINGTON, Va., Nov. 19 The Child Welfare League of America ... Rights of the Child (CRC), the American Psychological Association, and the ... Children,s Health Issues and The Convention on the Rights of the ...
Cached Medicine News:Health News:Health Plans Propose Guaranteed Coverage for Pre-Existing Conditions and Individual Coverage Mandate 2Health News:Health Plans Propose Guaranteed Coverage for Pre-Existing Conditions and Individual Coverage Mandate 3Health News:Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately 2Health News:Growth Hormone Boost May Not Slow Alzheimer's 2Health News:Growth Hormone Boost May Not Slow Alzheimer's 3Health News:Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting 2Health News:Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting 3Health News:Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting 4Health News:InVitria to Launch "BE FREE" Promotion at TERMIS '08 in San Diego 2Health News:Linda Spears, CWLA Vice President of Policy Will Speak at Senate Briefing 2
... November 2005. Specifications, including colors, subject to ... lb (2.3 kg), FreeStyle by AirSep is ... for those patients who know no boundaries. ... FreeStyle captures the heart of what it ...
... is AirSep Corporations most economical line of ... lpm of therapeutic oxygen in home, hospital, ... of units in daily use throughout the ... known for high performance, easy maintenance, and ...
... to 10 LPM of oxygen reducing the delivery ... M10 is engineered to reduce the cost of ... fewer parts than any other concentrator on the ... you to reduce expenditure on accessories and unnecessary ...
... conserver, it's important to have a choice that ... name synonymous with innovative excellence, offers two great ... automatic and value packed conservers., ,With its ... used 8 hours a day for 3 to ...
Medicine Products: